TY - JOUR
T1 - Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia
T2 - High incidence of early complete and major cytogenetic responses
AU - Kantarjian, Hagop M.
AU - Cortes, Jorge E.
AU - O'Brien, Susan
AU - Giles, Francis
AU - Garcia-Manero, Guillermo
AU - Faderl, Stefan
AU - Thomas, Deborah
AU - Jeha, Sima
AU - Rios, Mary Beth
AU - Letvak, Laurie
AU - Bochinski, Kathy
AU - Arlinghaus, Ralph
AU - Talpaz, Moshe
PY - 2003/1/1
Y1 - 2003/1/1
N2 - Fifty patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in early chronic phase received imatinib mesylate, 400 mg orally daily. After a median follow-up of 9 months, 49 patients (98%) achieved a complete hematologic response and 45 patients (90%) achieved a major cytogenetic response, complete in 36 patients (72%). Compared with similar patients who received interferon-α with or without hydroxyurea or other interferon-α combination regimens, those receiving imatinib mesylate had higher incidences of complete and major (Ph < 35%) cytogenetic responses at 3 months (34% and 74% versus 1%-4% and 9%-24%, respectively), 6 months (52% and 80% versus 3%-7% and 11%-28%, respectively), and 9 months (60% and 77% versus 5%-11% and 14%-30%, respectively; P < .001). Competitive quantitative polymerase chain reaction (QPCR) studies at 9 months showed a median QPCR value (ratio of BCR-ABL/ABL transcripts x 100) of 0.59% overall and of 0.24% (range, 0.001%-29.5%) for complete cytogenetic response.
AB - Fifty patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in early chronic phase received imatinib mesylate, 400 mg orally daily. After a median follow-up of 9 months, 49 patients (98%) achieved a complete hematologic response and 45 patients (90%) achieved a major cytogenetic response, complete in 36 patients (72%). Compared with similar patients who received interferon-α with or without hydroxyurea or other interferon-α combination regimens, those receiving imatinib mesylate had higher incidences of complete and major (Ph < 35%) cytogenetic responses at 3 months (34% and 74% versus 1%-4% and 9%-24%, respectively), 6 months (52% and 80% versus 3%-7% and 11%-28%, respectively), and 9 months (60% and 77% versus 5%-11% and 14%-30%, respectively; P < .001). Competitive quantitative polymerase chain reaction (QPCR) studies at 9 months showed a median QPCR value (ratio of BCR-ABL/ABL transcripts x 100) of 0.59% overall and of 0.24% (range, 0.001%-29.5%) for complete cytogenetic response.
UR - http://www.scopus.com/inward/record.url?scp=0037222235&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037222235&partnerID=8YFLogxK
U2 - 10.1182/blood-2002-02-0545
DO - 10.1182/blood-2002-02-0545
M3 - Article
C2 - 12393600
AN - SCOPUS:0037222235
SN - 0006-4971
VL - 101
SP - 97
EP - 100
JO - Blood
JF - Blood
IS - 1
ER -